➤ HER2 testing is critical because HER2-positive patients may benefi t from trastuzumab therapy, which has been shown to signifi cantly improve response rates, time to disease progression, and overall survival.
➤ Immunohistochemistry and fl uorescence in situ hybridization (FISH) have been approved for the determination of HER2 status; however, FISH has demonstrated superior sensitivity and specifi city. Patients with HER2 gene amplifi cation by FISH have been shown to benefi t from trastuzumab therapy.
B
reast cancer is the most commonly diagnosed cancer among women and the second leading cause of cancer death (Jemal et al., 2005) . The American Cancer Society estimated that more than 211,000 new cases of breast cancer would be diagnosed in the United States in 2005 and more than 40,000 women would die as a result of the disease (Jemal et al.) . Breast cancer survival is determined by a variety of prognostic and predictive indicators. Breast cancer's prognostic factors (e.g., tumor size and type, number of positive lymph nodes, nuclear grade, absence or presence of estrogen and/or progesterone receptors) (National Comprehensive Cancer Network [NCCN], 2005; Rosenzweig, Rust, & Hoss, 2000) infl uence the clinical outcome of the disease regardless of treatment, whereas predictive factors, such as HER2 overexpression or amplifi cation, correlate with prognosis because they are linked to patients' responses to particular therapies.
Several newly recognized prognostic and predictive factors have begun to be used in the management of breast cancer (NCCN, 2005) . One factor is the human epidermal growth factor receptor-2, or HER2. Overexpression of HER2 is associated strongly with a poor prognosis in breast cancer, indicating a more aggressive disease and shortened overall survival (Slamon et al., 1987 (Slamon et al., , 1989 . The fi ve-year overall survival rate for HER2-positive patients is signifi cantly shorter than for those who are HER2 negative (58% versus 77%, respectively; p = 0.004) (Sjogren, Inganas, Lindgren, Holmberg, & Bergh, 1998) . Using multivariate survival analysis, Slamon et al. (2001) found HER2 gene amplifi cation to be more predictive for clinical outcome than any other prognostic factor, with the exception of the number of positive lymph nodes (Slamon et al., 1987 (Slamon et al., , 1989 Data Sources: Published articles and abstracts, online resources, a clinical handbook, and product information.
Data Synthesis: HER2 gene amplifi cation or HER2 protein overexpression can be found in 20%-25% of breast cancers and is important pathogenic and prognostic information. HER2 also predicts patient response to trastuzumab. Patients with HER2-positive metastatic breast cancer benefi t from trastuzumab whether selected by immunohistochemistry, which measures the HER2 protein, or fl uorescence in situ hybridization (FISH), which measures the HER2 oncogene. However, patients who are identifi ed accurately as HER2 gene-amplifi ed by FISH derive the greatest benefi t.
Conclusions: Accurate testing is crucial for appropriate identifi cation of patients for trastuzumab therapy. FISH is the most reproducible and accurate method.
Implications for Nursing: Education regarding HER2 testing and trastuzumab helps patients to make informed decisions and facilitates active participation in their care as well as enhances dialogue with physicians. This material is protected by U.S. copyright law. Unauthorized reproduction is prohibited. To purchase quantity reprints, please e-mail reprints@ons.org or to request permission to reproduce multiple copies, please e-mail pubpermissions@ons.org.
